Company news

Atara Biotherapeutics, Inc. news in 2022

Atara Biotherapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

December 19, 2022

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

December 18, 2022

Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress

November 7, 2022

Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

October 31, 2022

CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

October 13, 2022

Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre

September 27, 2022

Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update

August 7, 2022

Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

July 11, 2022

Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022

July 5, 2022

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

June 3, 2022

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

May 18, 2022

Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress

May 4, 2022

Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer

April 4, 2022

Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm

April 3, 2022

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 3, 2022

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

February 27, 2022

Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial

February 17, 2022

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

February 16, 2022

Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm

January 25, 2022

Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension

January 5, 2022

Calls in 2022

Decks in 2022